Significance of P-glycoprotein expression in childhood malignant tumors

Neoplasma

Volumn 48, Issue 6, 2001, Pages 472-478

  Kucerova H ^a   Sumerauer, D ^a   Drahokoupilova E ^a   Piskova M ^a   Bedrnicek J ^a   Eckschlager, T ^a  

^a UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

Author keywords

Childhood malignant tumors; Flow cytometry; Multidrug resistance; P glycoprotein

Indexed keywords

GLYCOPROTEIN P;

ARTICLE; BRAIN TUMOR; CANCER RECURRENCE; CHILD; CHILDHOOD CANCER; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; HEPATOBLASTOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; METASTASIS; MULTIDRUG RESISTANCE; NEPHROBLASTOMA; NEUROBLASTOMA; PROTEIN EXPRESSION; SOFT TISSUE SARCOMA;

EID: 0035713318     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Does P-glycoprotein play a role in clinical resistance of malignant astrocytoma
2. Altered expression of resistance associated genes in hepatoblastoma xenografts incorporated into mice following treatment with adriamycin or cisplatin
3. P-glycoprotein expression is a marker for chemotherapy resistance and prognosis in advanced ovarian cancer
4. Methods to detect P-glycoprotein- associated multidrug resistance in patients tumors: Consensus recommendations
5. Multidrug resistance in childhood malignancies
6. Bovine seminal ribonuclease selectively kills human multidrug-resistant neuroblastoma cells via induction of apoptosis
7. Expression of the MDR1 gene product P-glycoprotein in childhood neuroblastoma
8. Mechanisms of drug resistance in human lung cancer cells
9. The P-glycoprotein multidrug transporter
10. Drug resistance in acute myeloid leukemia: A comparative analysis
11. P-glycoprotein expresion in normal and reactive bone marrows
12. P-glycoprotein levels predict poor outcome in patients with osteosarcoma
13. Reference method for detection of PGP mediated multidrug resistance in human hematological malignancies: A method validated by the laboratories of the French Drug Resistance Network
14. Comparison of three commercially avaible antibodies for flow cytometric monitoring of P-glycoprotein expression in tumor cells
15. Drug retention, efflux, and resistance in tumor cells
16. Flow cytometric analysis of P-glycoprotein expression and drug efflux in human soft tissue and bone sarcomas
17. Multidrug resistance in glioblastoma. Chemosensitivity testing and immunohistochemical demonstration of P-glycoprotein
18. Detection of activity of P-glycoprotein in human tumour samples using rhodamine 123
19. Autologous bone marrow purging by in situ IL-2 activation of endogenous killer cells
20. Improved flow-cytometric detection of low P-glycoprotein expression in leukaemic blasts by histogram subtraction analysis
21. Expression of P-glycoprotein in hepatocellular carcinoma. A determinant of chemotherapy response
22. MDR (Multiple Drug Resistant) type of resistance to chemotherapy in clinical practice
23. Specific detection of multidrug resistance proteins MRP1, MRP2, MRP3, MRP5, and MDR3 P-glycoprotein with a panel of monoclonal antibodies
24. Multidrug resistance gene P-glycoprotein expression in gastric adenocarcinoma and precursor lesions
25. Predicting chemoresistance in human malignant glioma cells: The role of molecular genetic analysis
26. Clinical significance of P-glycoprotein expression and function for response to induction chemotherapy, relapse rate and overall survival in acute leukemia